Lymphoproliferative disorders Clinical Trials

A listing of Lymphoproliferative disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 202 clinical trials
LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

The primary objective of Phase I is to establish the maximum tolerated dose (MTD) of ruxolitinib in combination with carfilzomib and dexamethasone. The primary objective of phase II is to evaluate progression-free survival (PFS) at 4 months in multiple myeloma subjects who receive the combination treatment carfilzomib, dexamethasone, and ruxolitinib.

platelet count
cancer
dexamethasone
refractory multiple myeloma
bone marrow procedure
  • 19 views
  • 26 Sep, 2021
  • 2 locations
Daratumumab Carfilzomib Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed Multiple Myeloma

The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab, carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.

platelet count
carfilzomib
corticosteroids
dexamethasone
lenalidomide
  • 0 views
  • 24 Sep, 2021
  • 1 location
Strength Training in Improving Pain and Quality of Life in Patients With Multiple Myeloma

This trial studies how well strength training works in improving bone health, pain, and quality of life in patients with multiple myeloma. Weekly physical activity may improve bone recovery, reduce pain, and increase quality of life in patients with multiple myeloma.

  • 0 views
  • 17 Sep, 2021
  • 1 location
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Phase 1 of the study is comprised of an open-label, single ascending dose (SAD), multiple cohort study; a multiple dose cycle administration cohort study; and a combination administration study of P-BCMA-101 autologous T stem cell memory (Tscm) CAR-T cells in patients with relapsed / refractory MM. Followed by a Phase …

proteasome inhibitor
immunomodulatory imide drug
bcma
line of therapy
  • 352 views
  • 21 Sep, 2021
  • 16 locations
CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma

Patients with relapsed/refractory multiple myeloma will be enrolled in a dose-escalation phase receiving monotherapy CID-103. Once the recommended CID-103 dose and infusion duration is known, additional patients will be enrolled in an expansion phase consisting of two cohorts (anti-CD38 pretreated, and anti-CD38 treatment nave). Patients will be treated until disease …

  • 0 views
  • 26 Sep, 2021
  • 3 locations
A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma

This is a Phase 1, multicenter, open label, study of CC-95266 in subjects with relapsed and/or refractory multiple myeloma. The study will consist of two parts: dose escalation (Part A) and dose expansion (Part B). The dose escalation (Part A) of the study will evaluate the safety and tolerability of …

fludarabine
refractory multiple myeloma
bortezomib
progressive disease
measurable disease
  • 0 views
  • 27 Sep, 2021
  • 11 locations
Efficacy of Carfilzomib in Combination With Ibrutinib in Waldenstr m's Macroglobulinemia

In Waldenstrm macroglobulinemia (WM) chemotherapy induces only low CR/VGPR (Complete Remission/ Very Good Partial Response) rates and responses of short duration compared to other indolent lymphomas. Thus, innovative approaches are needed which combine excellent activity and tolerability in WM. Chemotherapy-free approaches are highly attractive for this patient group. Based on …

anemia
dexamethasone
fever
monoclonal antibody therapy
lymphoma
  • 0 views
  • 17 Sep, 2021
  • 11 locations
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

them from getting worse. To test the safety of the drug. Eligibility People 12 and older who have Epstein-Barr Virus (EBV)-positive lymphoproliferative disorders

cancer
hodgkin's disease
follicle stimulating hormone
lymphoma
ct scan
  • 173 views
  • 26 Sep, 2021
  • 1 location
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

Background The new drug LMP744 damages DNA. This causes cell death. Researchers want to see if it can treat certain kinds of cancer. They want to understand how the drug works and how it affects the body. Objective To test the safety of LMP744 and find out the dose of …

cancer
tumor cells
anticancer agents
solid tumour
white blood cells
  • 44 views
  • 12 Sep, 2021
  • 2 locations
An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma, refractory or resistant to standard therapy, or without available standard or curative therapy.

cancer
lymphoma
solid tumor
solid tumour
measurable disease
  • 16 views
  • 15 Sep, 2021
  • 6 locations